<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951818</url>
  </required_header>
  <id_info>
    <org_study_id>201903041RINB</org_study_id>
    <nct_id>NCT03951818</nct_id>
  </id_info>
  <brief_title>Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major</brief_title>
  <official_title>Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with thalassemia major have many endocrine diseases, such as hypopituitarism,
      hypothyroidism, hypoparathyroidis, osteoporosis, and etc.. These problems may be due to
      anemia itself or related to iron deposition. This study aimed to investigate the endocrine
      aspect of thalassemia major patients in Taiwan in order to introduce early intervention or
      treatment in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal bone mineral density rate</measure>
    <time_frame>10 years</time_frame>
    <description>abnormal bone mineral density is defined as T-score &lt; -1 SD in menopause women or men older than 50 years old, or Z score &lt; -2 SD in premenopausal women or men not older than 50 year old.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abnormal thyroid function rate</measure>
    <time_frame>10 years</time_frame>
    <description>abnormal thyroid function is defined as abnormal free thyroxine or abnormal thyrotropin. Normal range of free thyroxine is 0.6-1.75 ng/dl. normal range of thyrotropin is 0.1-4.5 mU/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal pituitary function rate</measure>
    <time_frame>10 years</time_frame>
    <description>abnormal pituitary function is defined as any of the abnormality in serum adrenocorticotropin (pg/l), IGF-1 (ng/ml). thyrotropin (mU/l), FSH (U/l), LH (U/l)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thalassemia Major</condition>
  <eligibility>
    <study_pop>
      <textblock>
        20-85 years old thalassemia major patients treated in the OPD of NTUH
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Thalassemia major

          -  Patients of 20-85 years old

        Exclusion Criteria:

          -  Patients younger than 20 years old.

          -  Patients older than 85 years old.

          -  Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyang-Rong Shih, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyang-Rong Shih, MD, PhD</last_name>
    <phone>+886-972653337</phone>
    <email>srshih@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shyang-Rong Shih</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyang-Rong Shih</last_name>
      <phone>886-23123456</phone>
      <email>srshih@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

